Tag Archives: Mayank Mamtani

B.Riley FBR Maintains Their Buy Rating on Allena Pharmaceuticals (ALNA)

B.Riley FBR analyst Mayank Mamtani maintained a Buy rating on Allena Pharmaceuticals (ALNA – Research Report) today and set a price target of $11.00. The company’s shares closed last Monday at $2.31, close to its 52-week low of $1.55. According

Akari Therapeutics (AKTX) Initiated with a Buy at B.Riley FBR

Akari Therapeutics (AKTX – Research Report) received a Buy rating and a $7.00 price target from B.Riley FBR analyst Mayank Mamtani today. The company’s shares closed last Monday at $1.92, close to its 52-week low of $1.56. According to TipRanks.com,

Novavax (NVAX) Gets a Buy Rating from B.Riley FBR

B.Riley FBR analyst Mayank Mamtani maintained a Buy rating on Novavax (NVAX – Research Report) today and set a price target of $12.00. The company’s shares closed last Monday at $3.75, close to its 52-week low of $3.54. According to

Genfit SA (GNFT) Receives a Buy from B.Riley FBR

B.Riley FBR analyst Mayank Mamtani reiterated a Buy rating on Genfit SA (GNFT – Research Report) today and set a price target of $43.00. The company’s shares closed last Monday at $16.18. According to TipRanks.com, Mamtani is a 5-star analyst

Medicines Co (MDCO) Gets a Buy Rating from B.Riley FBR

B.Riley FBR analyst Mayank Mamtani reiterated a Buy rating on Medicines Co (MDCO – Research Report) yesterday and set a price target of $95.00. The company’s shares closed last Monday at $51.98, close to its 52-week high of $58.48. According

Galectin Therapeutics (GALT) Receives a Buy from B.Riley FBR

In a report released today, Mayank Mamtani from B.Riley FBR maintained a Buy rating on Galectin Therapeutics (GALT – Research Report), with a price target of $8.00. The company’s shares closed last Monday at $3.53. According to TipRanks.com, Mamtani is